We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Intermittent Antimalaria Treatment With SP in African Children

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00168948
Recruitment Status : Unknown
Verified February 2003 by Charite University, Berlin, Germany.
Recruitment status was:  Active, not recruiting
First Posted : September 15, 2005
Last Update Posted : November 2, 2005
Deutscher Akademischer Austausch Dienst
Information provided by:
Charite University, Berlin, Germany

Brief Summary:
- intermittent preventive treatment with SP in children to evaluate efficacy and safety of this drug combination in children in northern Ghana

Condition or disease Intervention/treatment Phase
Malaria Anemia Drug: Sulfadoxin (12.5) Pyrimethamine (250 mg) Phase 4

Detailed Description:
  • Sulfadoxine and pyrimethamine have long been used for malaria prevention and treatment. In this study, following suggestions of WHO, these drugs are used for intermittent treatment.
  • It will be tested if this approach reduces the number of malaria attacks and ameliorates the severity of the disease
  • It will also be determined if anemia due to malaria, which is prevalent in northern Ghana, may be reduced
  • Moreover, the interaction between red cell polymorphisms such as HbS, HbC, alpha-thalassemia and glucose-6-phosphate dehydrogenase deficiency and SP will be examined

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 1200 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Prevention
Official Title: Intermittent Treatment With Sulfadoxine-Pyrimethamine for Malaria Control in Children: A Randomised, Double Blind, and Placebo-Controlled Clinical Trial
Study Start Date : March 2003
Estimated Study Completion Date : August 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Malaria
U.S. FDA Resources

Primary Outcome Measures :
  1. Efficacy and safety of IPTi with SP
  2. Impact of IPTi on incidence on malaria attacks
  3. Impact of IPTi on anemia

Secondary Outcome Measures :
  1. Interaction between erythrocyte polymorphisms and SP
  2. Influence on parasite multiplicity
  3. Impact on child development

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   2 Months to 4 Months   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • informed consent by parents or guardian
  • no concomitant serious disease
  • age >2 months

Exclusion Criteria:

  • serious allergy or hypersensitivity to sulfonamides or pyrimethamine
  • no severe hepatic or renal dysfunction
  • serious breach of study protocol

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00168948

Sponsors and Collaborators
Charite University, Berlin, Germany
Deutscher Akademischer Austausch Dienst
Study Director: Frank Mockenhaupt, PhD Charite University-Medicine, Berlin, Germany

Additional Information:
ClinicalTrials.gov Identifier: NCT00168948     History of Changes
Other Study ID Numbers: 01KA0202-T
First Posted: September 15, 2005    Key Record Dates
Last Update Posted: November 2, 2005
Last Verified: February 2003

Keywords provided by Charite University, Berlin, Germany:
Intermittent preventive treatment
Malaria control

Additional relevant MeSH terms:
Protozoan Infections
Parasitic Diseases
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action